List of Baxdela drug patents

Baxdela is owned by Melinta.

Baxdela contains Delafloxacin Meglumine.

Baxdela has a total of 13 drug patents out of which 0 drug patents have expired.

Baxdela was authorised for market use on 19 June, 2017.

Baxdela is available in tablet;oral dosage forms.

Baxdela can be used as treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults.

Drug patent challenges can be filed against Baxdela from June, 2026.

The generics of Baxdela are possible to be released after 27 February, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9539250 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(2 years from now)

US8273892 MELINTA Salt and crystalline forms thereof of a drug
Aug, 2026

(3 years from now)

US8871938 MELINTA Process for making quinolone compounds
Sep, 2029

(6 years from now)

USRE46617 MELINTA Process for making quinolone compounds
Dec, 2029

(6 years from now)

US7728143 MELINTA Salt and crystalline forms thereof of a drug
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8969569 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(2 years from now)

US8648093 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(2 years from now)

US8252813 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2026

(3 years from now)

US8410077 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9200088 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US7635773 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9750822 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9493582 MELINTA Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 19, 2022
New Indication (I) Oct 24, 2022
Generating Antibiotic Incentives Now (GAIN) Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in